Get the Stockscreener App
224.77
0.08%
-0.18
After Hours:
224.75
-0.02
-0.01%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $224.77, with a volume of 4.57M.
It is down -0.08% in the last 24 hours and up +10.84% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$224.95
Open:
$226.01
24h Volume:
4.57M
Relative Volume:
0.72
Market Cap:
$397.12B
Revenue:
$62.82B
Net Income/Loss:
$3.60B
P/E Ratio:
110.87
EPS:
2.0274
Net Cash Flow:
$19.98B
1W Performance:
-0.08%
1M Performance:
+10.84%
6M Performance:
+0.35%
1Y Performance:
+17.37%
1-Day Range:
$224.04
$227.55
1-Week Range:
$221.16
$230.47
52-Week Range:
$181.73
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
224.77 | 397.44B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,160.95 | 1.01T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
238.33 | 574.10B | 96.36B | 21.04B | 17.80B | 8.6488 |
MRK
Merck Co Inc
|
120.76 | 294.13B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.92 | 282.63B | 54.66B | 13.58B | 16.05B | 7.0171 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Diabetic Retinopathy Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Genentech, Ionis Pharma, AstraZeneca, Regenxbio, AbbVie, Palatin Techn, Avirmax - Barchart.com
AbbVie Loses Colorado 340B Drug Pricing Law Challenge - Law360
AbbVie: Growth-Pharma Profile At A Value-Pharma Price (NYSE:ABBV) - Seeking Alpha
Up 45% Since 2024: 1 Glaring Reality That Makes AbbVie Stock a Hold at $225 - Yahoo Finance
Is AbbVie Inc. (ABBV) A Good Stock To Buy Now? - Insider Monkey
Will Skyrizi & Rinvoq Continue to Drive AbbVie's Topline Through 2026? - TradingView
Zions Bancorporation National Association UT Sells 12,395 Shares of AbbVie Inc. $ABBV - MarketBeat
M Holdings Securities Inc. Takes Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie, Devon Energy And More On CNBC's 'Final Trades' - Benzinga
AbbVie Inc. $ABBV Shares Acquired by Wellspring Financial Advisors LLC - MarketBeat
Saturna Capital Corp Purchases 31,143 Shares of AbbVie Inc. $ABBV - MarketBeat
Smithbridge Asset Management Inc. DE Buys 18,364 Shares of AbbVie Inc. $ABBV - MarketBeat
Signet Private Wealth LLC Invests $1.20 Million in AbbVie Inc. $ABBV - MarketBeat
Townsquare Capital LLC Has $6.98 Million Stake in AbbVie Inc. $ABBV - MarketBeat
Illinois Municipal Retirement Fund Lowers Position in AbbVie Inc. $ABBV - MarketBeat
Janney Montgomery Scott LLC Grows Position in AbbVie Inc. $ABBV - MarketBeat
Dorsey & Whitney Trust CO LLC Reduces Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. stock (US00287Y1091): investors eye Skyrizi/Humira dynamics after recent data update - AD HOC NEWS
Final Trades: AbbVie, Devon Energy and the 2-Year and 10-Year Treasuries - CNBC
Allergan Aesthetics Releases 'The Aesthetics Evolution: What Consumers Really Want' Highlighting Consumer Motivations and Expectations in Aesthetics - AbbVie News Center
AbbVie's migraine drug cleared for migraine attacks on NHS - pharmaphorum
Stonebrook Private Inc. Sells 8,844 Shares of AbbVie Inc. $ABBV - MarketBeat
9,254 Shares in AbbVie Inc. $ABBV Purchased by North Dallas Bank & Trust Co. - MarketBeat
Deutsche Bank AG Raises Position in AbbVie Inc. $ABBV - MarketBeat
Novartis, AbbVie Lose Bid To Halt Wash. 340B Pharmacy Law - Law360
NICE backs AbbVie’s Aquipta for acute migraine treatment - The Pharma Letter
AbbVie Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
AbbVie (ABBV) Is Proving the Post-Humira Story Is About Skyrizi, Rinvoq, and Portfolio Depth - AlphaStreet
ABBV: Growth driven by immunology, oncology, neuroscience, and obesity, with robust pipeline progress - TradingView
7 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), GMR Solutions, Inc. Class A (GMRS) and Cullinan Management (CGEM) - The Globe and Mail
AbbVie Inc. stock underperforms Monday when compared to competitors - MarketWatch
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026? - The Motley Fool
AbbVie Inc. stock (US00287Y1091): FDA decision and pipeline catalysts keep focus on growth - AD HOC NEWS
Should You Buy, Sell or Hold ABBV Stock After It Rises 12% in a Month? - The Globe and Mail
Inflammatory Bowel Disease Market Gains Momentum with Expanding Pipeline and Investment Potential by 2036 – DelveInsight | AbbVie, Janssen Pharma, Abivax, Morphic Therapeutic, Eli Lilly, Gilead - Barchart.com
AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026 - Investing News Network
Is AbbVie Stock The Right Defensive Pick In This Volatile Market? - Trefis
AbbVie brings new blood cancer trial results to European doctors - Stock Titan
AbbVie, UnitedHealth, Sabra Health Care And A Consumer Defensive Stock On CNBC's 'Final Trades' - Benzinga
AbbVie Stock Price Target $350: Why TIKR Model Shows Around 54% Upside From Here - TIKR.com
Clearbridge Investments LLC Sells 204,014 Shares of AbbVie Inc. $ABBV - MarketBeat
Is AbbVie the Most Underrated Dividend Growth Stock in the S&P 500? - The Globe and Mail
ING Groep NV Trims Stock Position in AbbVie Inc. $ABBV - MarketBeat
DB&C Advisors LLC Purchases New Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Acquired by Capital International Investors - MarketBeat
AbbVie Inc. $ABBV Shares Acquired by Capital World Investors - MarketBeat
Capital Research Global Investors Acquires 177,370 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Purchased by Capital International Sarl - MarketBeat
AbbVie Inc. $ABBV Shares Sold by Dearborn Partners LLC - MarketBeat
Capital Group Private Client Services Inc. Purchases 6,065 Shares of AbbVie Inc. $ABBV - MarketBeat
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.40%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):